Business
Nexien BioPharma Announces Executive and Business Updates
Nexien BioPharma Announces Executive and Business Updates.
About this update from Nexien Biopharma, Inc.
[{"type":"text","content":"\n \n Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB:NXEN), a next \n generation biopharmaceutical company focused on research, development \n and commercialization of novel FDA-compliant cannabinoid pharmaceuticals \n and related drug delivery systems, today announced executive and \n business updates.\n \n \n Dr. Joseph F. Aceto, JD, Ph.D. has been appointed as the Company’s \n Interim Director of Translational Research. In this role, Dr. Aceto will \n oversee the ongoing evolution of Nexien’s research programs, to develop, \n license, and commercialize pharmaceuticals utilizing cannabinoids as the \n Active Pharmaceutical Ingredients (APIs). Dr. Aceto has more than 30 \n years of scientific, business, legal, and intellectual property \n experience, with a focus on supporting patented technologies in the \n pharmaceutical and biotechnology industries. Dr. Aceto will retain his \n existing role as Vice President, Legal and Intellectual Property counsel.\n \n \n Dr. Michael Fenn, Ph.D., a member of Nexien’s Scientific Advisory Board, \n has joined Harvard Innovation Labs as Director, Healthcare and Life \n Sciences. Dr. Fenn has over a decade of experience in life science and \n advanced materials research and development with a diverse background in \n nanomaterials, biomaterials, oncology, drug delivery, medical devices, \n and diagnostics. He has been involved with the launch and growth of \n multiple successful early-stage life science startups, directing \n pre-clinical R&D efforts, overseeing intellectual property development, \n and guiding overall business and scientific strategy.\n \n \n Nexien also announced that it has withdrawn its listing application with \n the Canadian Stock Exchange (“CSE”) based on indications from the \n Ontario Securities Commission of a protracted application process and \n timeline. While the Company may reconsider applying at the appropriate \n time for a listing on the CSE, management has determined to focus its \n resources on advancing its research and development programs.\n \n \n Alex Wasyl, Nexien’s Chief Executive Officer, commented, “Joe and Mike \n are great examples of the high-caliber, specialized talent we have \n attracted to Nexien’s team. I congratulate each of them on their new \n roles an...